GLP-1 receptor agonists are medications used to treat Type 2 diabetes that help regulate blood sugar by increasing insulin release, slowing digestion and reducing appetite
Its no wonder the global GLP-1 market is already worth $47.4 billionand set to grow tenfold by 2032
All of this makes the findings from our study on the anti-inflammatory impact of semaglutide in the population without T2DM, mostly with obesity and pre-diabetes, of clinical relevance as well
Curr Protoc In Pharmacol

Contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndromes (MEN 2) Not suitable for individuals with type 1 diabetes or diabetic ketoacidosis Should not be used alongside other GLP-1 receptor medications Gastric emptying may be delayed, requiring caution for procedures involving sedation or general anesthesia due to aspiration risk Use caution in those with a history of diabetic retinopathy 1-3 Consult your healthcare provider if you have a history of pancreatitis, as the medication may increase risk Serious side effects may involve hypoglycemia, kidney issues, or allergic reactions Avoid use during pregnancy and breastfeeding 1 Enhances glucose-dependent insulin secretion Suppresses glucagon secretion Slows gastric emptying Influences brain regions involved in appetite regulation, leading to reduced hunger and caloric intake Improves insulin sensitivity 1-3 Supports weight loss Helps to minimize internal inflammation and improves cardiometabolic health measures 5 Q: How long does it take to see results

Side note: if you like the details, check out this blog post on gut health and weight management, and the bacterial superstar, Akkermansia muciniphila , thats been shown to promote weight loss